Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Tolerability of EGb 761 in Raynaud's Phenomenon
NCT00251238Phase 2Completed
- Sponsor
- VSM Geneesmiddelen
- Start
- Nov 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary Raynaud's Phenomenon comparing Ginkgo biloba extract EGb 761 with Placebo (2 arms). Primary endpoints: Frequency of Vasospastic Attacks at 10 weeks, Duration of Vasospastic Attacks at 10 weeks and 1 more. Started Nov 2005; status: completed.
02
Drugs
ginkgo biloba extract
03
Conditions
Primary Raynaud's Phenomenon
Beyond the preview
Go deeper on NCT00251238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251238.